Human EpCAM x Human CD3 Bispecific Antibody

Solitomab scFv antibody - Recombinant

ABOUT

Monoclonal scFv antibody against human EpCAM and human CD3

Anti-hEpCAM-CD3 is a bispecific antibody that recognizes two human cell markers: human epithelial cell adhesion molecule (hEpCAM) and hCD3. It features solitomab's single-chain variable fragments (scFv) joined by a glycine-serine linker and a hexahistidine-tag (His6).

Solitomab was developed for the treatment of relapsed/refractory EpCAM-positive solid tumors [1]. By binding to hCD3 and hEpCAM, this dual-targeting antibody engages unstimulated T cells to proliferate and subsequently trigger T cell-mediated lysis of hEpCAM-positive cells (see figure).

More details More details

 

Key features

  • Reacts with human EpCAM and human CD3
  • ScFv of clinical relevant bispecific mAb solitomab
  • Hexahistidine (His6) tag
  • Provided azide-free
  • Each lot is functionally tested

Applications

  • Adjustment studies of cancer cell contact-dependent killing
  • Improving T cell activation

 

1. Kebenko M, et al., 2018. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology. 7(8):e1450710

All products are for research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Target

CD3, EpCAM

Target species

Human

Species
Human
Isotype
None (scFv)
Clone
Solitomab, AMG 110, MT110
CAS number
1005198-65-1
Synonyms
AMG 110
MT110
Tag
His6
Source
CHO cells
Purification
HisTrap affinity chromatography
Formulation buffer

Sodium phosphate buffer, saccharose

Preservative
Azide-free
Purity
> 90 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay

Tested applications

Cellular assays, ELISA, flow cytometry

Quality control

Each lot is validated by flow cytometry.

CONTENTS

Contents

  • Product: 
    Anti-hEpCAM-CD3
  • Cat code: 
    bimab-ecamcd3-01
  • Quantity: 
    10 µg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20 °C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

EpCAM

The human epithelial cell adhesion molecule (EpCAM, CD326, Trop1) is a transmembrane, 40 kDa glycoprotein highly abundant in almost all human carcinomas, including colon, prostate, ovarian, or breast cancer [1]. In healthy tissue, EpCAM expression is generally low [1-2]. In cancer, EpCAM overexpression is responsible for tumor proliferation, invasion, and migration and is often correlated with a poor prognosis [1]. Thus, EpCAM represents an attractive therapeutic target. The number of EpCAM-positive cancers with limited therapeutic options at the advanced stage formed the rationale for developing the EpCAM/CD3 BiTE® antibody solitomab (MT110, AMG 110) [1]. 

CD3

The cluster of differentiation 3 (CD3, formerly named T3) is a multimeric protein complex consisting of four polypeptides (CD3ε, CD3γ, CD3δ, and CD3ζ) that assemble as three dimers (εγ, εδ, and ζζ) [4]. It is a marker of T cells, which recognizes and participates in the elimination of infected cells and tumor cells through the interaction between the TCR (T cell receptor) on T cells and the MHC-peptide complex on antigen-presenting cells [4-5]. Because of its short cytoplasmic tail, the TCR lacks the ability to signal and requires non-covalent association with the CD3. Upon antigen recognition, T cells' TCR/CD3 complex triggers downstream intracellular signaling and activates T cell cells [4].

 

References:

1. Brischwein K, et al., 2006. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 43(8):1129-43. 
2. Kebenko M, et al., 2018. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology. 7(8):e1450710.
3. Chetty R. & Gatter K., 1994. CD3: structure, function, and role of immunostaining in clinical practice. J. Pathol. 173(4):303-307.
4. Smith-Garvin J.E. et al., 2009. T Cell Activation. Ann. Rev. Immunol. 27:591-619.3. 

DOCUMENTS

Documents

Anti-hEpCAM-CD3

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?